LARS1 is a Prognostic Biomarker and Exhibits a Correlation with Immune Infiltrates in Hepatocellular Carcinoma

• Published in: International journal of general medicine 2024-01, Vol.17, p.2203-2221
• Main Authors: Fan, Longfei, Qin, Zhongqiang, Wu, Di, Yang, Yunchuan, Zhang, Yigang, Xie, Bo, Qian, Jingyu, Wei, Jianzhu, Wang, Zhaoying, Yang, Peipei, Qian, Zhen, Yuan, Mu, Zhu, Ziyi, Tan, Yulin, Tan, Yi
• Format: Article
• Language: English
• Subjects: bioinformatics analysis; biomarker; hepatocellular carcinoma; leucyl-trna synthetase 1; Original Research; the cancer genome atlas
• ISSN: 1178-7074; 1178-7074
• DOI: 10.2147/IJGM.S457577

To study the relationship between LARS1 expression and immune infiltration and prognosis in hepatocellular carcinoma (HCC). The clinical characteristics together with LARS1 expression levels were obtained from the TCGA database. Immunohistochemistry confirmed LARS1 expression levels in paraneoplastic and tumor tissues. To investigate LARS1-related downstream molecules, a network of protein-protein interactions (PPIs) and the Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) were built. Furthermore, gene set enrichment analysis (GSEA) was used to analyze the pathways associated with LARS1 expression, whereas Single-sample GSEA (ssGSEA) was applied to perform an association study between immune infiltration and LARS1 gene expression. The TISCH Database and the TISIDB database were used to compare the difference of LARS1 expression in hepatocellular carcinoma and immunomodulators. In comparison to that in normal tissues, the LARS1 expression level was elevated in tumor tissues. LARS1 expression exhibited substantial correlation with AFP, Histologic grade, pathologic stage, Residual tumor, and Vascular invasion in HCC. Higher LARS1 expression in HCC was linked to lower progression-free survival (PFS), disease-specific survival (DSS), and overall survival (OS). According to the GO/KEGG study, the important biological process (neutral lipid metabolic process), cellular component (triglyceride-rich plasma lipoprotein), molecular functions (lipase inhibitor activity), and KEGG pathway (cholesterol metabolism) could be a probable function mechanism in promoting HCC. Various pathways as per GSEA revealed that they were enriched in samples with elevated LARS1 expression. The expression level of LARS1 in malignant tumor cells after immunotherapy was significantly higher than that before immunotherapy. LARS1 was also remarkably linked to the infiltration level and the immunomodulators. LARS1 can be used as a biomarker of HCC, which is associated to immune infiltration of HCC.